Comparison of the protective immunity elicited by a Brucella cocktail protein vaccine (rL7/L12+rTOmp31+rSOmp2b) in two different adjuvant formulations in BALB/c mice

Golshani, Maryam; Amani, M.; Siadat, Seyed Davar; Nejati-Moheimani, Mehdi; Arsang, Amin

doi:10.1016/j.molimm.2018.10.002

Cited by 8 publications

(5 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Protective efficacy of SSVs and CSV was performed as previously described (Golshani et al ., 2018a,b; Li et al ., 2018a,b) with some modifications. In brief, mice were immunized using the above‐mentioned methods.…”

Section: Methodsmentioning

confidence: 99%

“…Based on previous results, combined subunit vaccine (CSV) using more than two recombinant proteins could confer higher potential immune response against Brucella infection than SSV. These CSVs include L7/L12‐SOmp2b (Golshani et al ., 2018a,b), L7/L12‐TOmp31‐SOmp2b (Golshani et al ., 2018a,b), L7/L12‐Omp25 (Paul et al ., 2018; Gupta et al ., 2020) and Adk‐SecB (Huy et al ., 2020a,b). Amongst these CSVs, recombinant proteins L7/L12 and OMPs are considered as potential immunogens, which can induce strong protective effects against Brucella infection.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Immunization with a combination of recombinant Brucella abortus proteins induces T helper immune response and confers protection against wild‐type challenge in BALB/c mice

Wang

Wei

et al. 2022

Microbial Biotechnology

View full text Add to dashboard Cite

Summary Protective efficiency of a combination of four recombinant Brucella abortus (B. abortus) proteins, namely, ribosomal protein L7/L12, outer membrane protein (OMP) 22, OMP25 and OMP31, was evaluated as a combined subunit vaccine (CSV) against B. abortus infection in RAW 264.7 cell line and murine model. Four proteins were cloned, expressed and purified, and their immunocompetence was analysed. BALB/c mice were immunized subcutaneously with single subunit vaccines (SSVs) or CSV. Cellular and humoral immune responses were determined by ELISA. Results of immunoreactivity showed that these four recombinant proteins reacted with Brucella‐positive serum individually but not with Brucella‐negative serum. A massive production of IFN‐γ and IL‐2 but low degree of IL‐10 was observed in mice immunized with SSVs or CSV. In addition, the titres of IgG2a were heightened compared with IgG1 in SSV‐ or CSV‐immunized mice, which indicated that SSVs and CSV induced a typical T‐helper‐1‐dominated immune response in vivo. Further investigation of the CSV showed a superior protective effect in mice against brucellosis. The protection level induced by CSV was significantly higher than that induced by SSVs, which was not significantly different compared with a group immunized with RB51. Collectively, these antigens of Brucella could be potential candidates to develop subunit vaccines, and the CSV used in this study could be a potential candidate therapy for the prevention of brucellosis.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Immunization with a combination of recombinant Brucella abortus proteins induces T helper immune response and confers protection against wild‐type challenge in BALB/c mice

Wang

Wei

et al. 2022

Microbial Biotechnology

View full text Add to dashboard Cite

show abstract

“…IL-10 is an immune-regulatory cytokine that induces the balance of Th1 or Th2 immune responses to prevent over activity of the immune system and limit further tissue damage ( 69 ). Numerous cell surface and intracellular components could be expressed by E. coli and serve as protective antigens in mouse models, such as outer Omp2b, OMP16, OMP19, L7/L12 ribosomal protein ( 70 – 72 ), Omp31 ( 73 ), outer membrane protein Omp25 ( 71 ), p39 (a putative periplasmic binding protein) ( 74 , 75 ), AsnC ( 76 ), Omp16 ( 77 ), lumazine synthase ( 78 ), rE2o ( 79 ), rCysK ( 80 ), DnaK ( 81 ), chimeric protein from OMP19 and p39 domains ( 75 ), OMP25-BLS fusion protein ( 82 ), OMP25c protein mixed with freund's adjuvant ( 83 ), and AspC, Dps, lnpB, and Ndk ( 84 ); however, none of them have shown a successful clearance. Previous studies have shown that combining several recombinant proteins which generate a wide array of immunogenicity could induce stronger immune responses and better protection against Brucella than their univalent counterparts ( 74 , 85 , 86 ).…”

Section: Subunit Vaccinesmentioning

confidence: 99%

“…Previous studies have shown that combining several recombinant proteins which generate a wide array of immunogenicity could induce stronger immune responses and better protection against Brucella than their univalent counterparts ( 74 , 85 , 86 ). Also, several studies have shown that subunit vaccines could induce protection levels and immune responses similar to those induced by live or attenuated vaccine strains ( 69 , 72 , 73 , 83 , 84 , 87 – 89 ). At the same time, other studies have not observed such findings ( 90 ).…”

Section: Subunit Vaccinesmentioning

confidence: 99%

Evaluation of Brucellosis Vaccines: A Comprehensive Review

Heidary

Dashtbin

Ghanavati³

et al. 2022

Front. Vet. Sci.

View full text Add to dashboard Cite

Brucellosis is a bacterial zoonosis caused by Brucella spp. which can lead to heavy economic losses and severe human diseases. Thus, controlling brucellosis is very important. Due to humans easily gaining brucellosis from animals, animal brucellosis control programs can help the eradication of human brucellosis. There are two popular vaccines against animal brucellosis. Live attenuated Brucella abortus strain 19 (S19 vaccine) is the first effective and most extensively used vaccine for the prevention of brucellosis in cattle. Live attenuated Brucella melitensis strain Rev.1 (Rev.1 vaccine) is the most effective vaccine against caprine and ovine brucellosis. Although these two vaccines provide good immunity for animals against brucellosis, the expense of persistent serological responses is one of the main problems of both vaccines. The advantages and limitations of Brucella vaccines, especially new vaccine candidates, have been less studied. In addition, there is an urgent need for new strategies to control and eradicate this disease. Therefore, this narrative review aims to present an updated overview of the available different types of brucellosis vaccines.

show abstract

“…It has been reported that the Omp28 peptide with CpG oligonucleotide as an adjuvant can induce an immune response mediated by IgG2a type, indicating that the Omp28 can induce the body to produce large amounts of IgG antibodies [ 20 ]. It has been known that vaccines constructed from a single protein stimulate poor immune responses and that multiple protein combinations enhance the vaccine's immune response [ 21 ]. Therefore, in this study, based on the T/B epitopes of Omp22, Omp19 and Omp28, a multi-epitope vaccine against Brucella was constructed.…”

Section: Introductionmentioning

confidence: 99%

Design of a new multi-epitope vaccine against Brucella based on T and B cell epitopes using bioinformatics methods

et al. 2021

View full text Add to dashboard Cite

Brucellosis is one of the most serious and widespread zoonotic diseases, which seriously threatens human health and the national economy. This study was based on the T/B dominant epitopes of Brucella outer membrane protein 22 (Omp22), outer membrane protein 19 (Omp19) and outer membrane protein 28 (Omp28), with bioinformatics methods to design a safe and effective multi-epitope vaccine. The amino acid sequences of the proteins were found in the National Center for Biotechnology Information (NCBI) database, and the signal peptides were predicted by the SignaIP-5.0 server. The surface accessibility and hydrophilic regions of proteins were analysed with the ProtScale software and the tertiary structure model of the proteins predicted by I-TASSER software and labelled with the UCSF Chimera software. The software COBEpro, SVMTriP and BepiPred were used to predict B cell epitopes of the proteins. SYFPEITHI, RANKpep and IEDB were employed to predict T cell epitopes of the proteins. The T/B dominant epitopes of three proteins were combined with HEYGAALEREAG and GGGS linkers, and carriers sequences linked to the N-and C-terminus of the vaccine construct with the help of EAAAK linkers. Finally, the tertiary structure and physical and chemical properties of the multi-epitope vaccine construct were analysed. The allergenicity, antigenicity and solubility of the multi-epitope vaccine construct were 7.37-11.30, 0.788 and 0.866, respectively. The Ramachandran diagram of the mock vaccine construct showed 96.0% residues within the favoured and allowed range. Collectively, our results showed that this multi-epitope vaccine construct has a high-quality structure and suitable characteristics, which may provide a theoretical basis for future laboratory experiments.

show abstract

Comparison of the protective immunity elicited by a Brucella cocktail protein vaccine (rL7/L12+rTOmp31+rSOmp2b) in two different adjuvant formulations in BALB/c mice

Cited by 8 publications

References 38 publications

Immunization with a combination of recombinant Brucella abortus proteins induces T helper immune response and confers protection against wild‐type challenge in BALB/c mice

Immunization with a combination of recombinant Brucella abortus proteins induces T helper immune response and confers protection against wild‐type challenge in BALB/c mice

Evaluation of Brucellosis Vaccines: A Comprehensive Review

Design of a new multi-epitope vaccine against Brucella based on T and B cell epitopes using bioinformatics methods

Contact Info

Product

Resources

About